Drug intelligence / Profile preview

HY1272

Development stage: Phase 1
Lead developer: Hengyi Biomedicine
Administration: Intravenous

Overview

HY1272 is an investigational antineoplastic agent in Phase 1 clinical development for the treatment of solid tumors, including locally advanced or metastatic solid tumors and EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC). It is being evaluated as monotherapy and in combination with osimertinib. Its mechanism of action has not been disclosed. Developed by Hengyi Biomedicine (Shanghai) and associated with Newsoara Biopharma. Administration is via intravenous infusion.

Beyond the preview

Go deeper on HY1272.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HY1272.

Explore the full profile